Patents Examined by Peter Johansen
  • Patent number: 11319380
    Abstract: Provided herein are chimeric antigen receptors (CARs) for cancer therapy, and more particularly, CARs containing a scFv from an anti-MUC16 monoclonal antibody. Provided are immune effector cells containing such CARs, and methods of treating proliferative disorders.
    Type: Grant
    Filed: June 4, 2019
    Date of Patent: May 3, 2022
    Assignee: PRECIGEN, INC.
    Inventors: Helen Sabzevari, Rutul R. Shah
  • Patent number: 11306149
    Abstract: Provided herein are agonistic antibodies, or antigen binding portions thereof, that bind to human CD40 and comprise improved heavy and light chain variable regions that impart improved yield and reduced aggregation. The invention also provides methods of treatment of cancer or chronic infection by administering the antibodies of the invention to a subject in need thereof.
    Type: Grant
    Filed: December 27, 2018
    Date of Patent: April 19, 2022
    Assignees: Bristol-Myers Squibb Company, CytomX Therapeutics, Inc.
    Inventors: Bryan C. Barnhart, Brigitte Devaux, Aaron P. Yamniuk, Shannon L. Okada, Brenda L. Stevens, James William West
  • Patent number: 11299545
    Abstract: Anti-HLA-C6 antibodies and antigen-binding fragments thereof are described. Also described are nucleic acids encoding the antibodies, compositions comprising the antibodies, methods of producing the antibodies, and methods of using the antibodies for treating or preventing diseases, such as autoimmune diseases.
    Type: Grant
    Filed: April 3, 2020
    Date of Patent: April 12, 2022
    Assignee: Janssen Biotech, Inc.
    Inventors: Ryan Eberwine, Anne Fourie, Paul H. Kim, Carl L. Manthey, Hong Zhou
  • Patent number: 11286289
    Abstract: The present invention relates to T cell receptors (TCRs) which bind the HLA-A*0201 restricted peptide GVYDGREHTV (SEQ ID NO: 1) derived from the MAGE-A4 protein. The TCRs of the invention demonstrate excellent specificity profiles for this MAGE epitope. Also provided are nucleic acids encoding the TCRs, cells engineered to present the TCRs, cells harbouring expression vectors encoding the TCRs and pharmaceutical compositions comprising the TCRs, nucleic acids or cells of the invention.
    Type: Grant
    Filed: October 8, 2018
    Date of Patent: March 29, 2022
    Inventors: Nicholas Tribble, William Lawrance, Eleanor Bagg
  • Patent number: 11242396
    Abstract: The invention relates to novel bispecific antigen binding molecules, comprising (a) at least one antigen binding domain capable of specific binding to Fibroblast Activation Protein (FAP) comprising FAP clone 212 or variants thereof, and (b) at least one antigen binding domain capable of specific binding to CD40, and to methods of producing these molecules and to methods of using the same.
    Type: Grant
    Filed: September 30, 2019
    Date of Patent: February 8, 2022
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Peter Bruenker, Harald Duerr, Christian Klein, Pablo Umana, Alexander Bujotzek, Joerg Zielonka, Christine Trumpfheller, Moritz Rapp, Marine Le Clech
  • Patent number: 11220670
    Abstract: In some embodiments, methods of delivering a therapeutically effective amount of an expanded number of tumor infiltrating lymphocytes obtained from tumor remnants to a patient in need thereof, for the treatment of a cancer, are disclosed.
    Type: Grant
    Filed: February 19, 2021
    Date of Patent: January 11, 2022
    Assignee: Iovance Biotherapeutics, Inc.
    Inventors: Michelle R. Simpson-Abelson, Christopher Mosychuk, Michael T. Lotze
  • Patent number: 11208485
    Abstract: Provided herein are binding polypeptides that specifically bind PD-1. More specifically, provided herein are fusion proteins, including multivalent and/or multispecific constructs and chimeric antigen receptors, that bind PD-1. Also provided are pharmaceutical compositions containing the polypeptides, nucleic acid molecules encoding the polypeptides and vectors and cells thereof, and methods of use and uses of the provided PD-1 binding polypeptides for treating diseases and conditions, such as cancer.
    Type: Grant
    Filed: October 11, 2019
    Date of Patent: December 28, 2021
    Assignee: InhibRx, Inc.
    Inventors: Rajay A. Pandit, John C. Timmer, Angelica N. Sanabria, Florian Sulzmaier, Brendan P. Eckelman
  • Patent number: 11186631
    Abstract: An anti-STAT3 specific antibody and a pharmaceutical composition comprising the same is provided. The anti-STAT3 specific antibody includes a site that specifically binds to STAT3, and further includes a STAT3 site plus a DNA binding site that confer cell penetration ability, and the pharmaceutical composition includes the anti-STAT3 specific antibody as an active ingredient. The STAT3 specific antibody, and particularly the STAT3/DNA dual specific antibody having a dual specific characteristic, contains a DNA binding site that can penetrate cells and specifically bind to DNA in the nucleus, and thus can overcome the limitations of conventional antibody therapeutics that can target only extracellular proteins. The antibody can inhibit transcription factor activity of STAT3 by specifically binding to phosphorylated activated form of STAT3. Thus, the antibody could be used for the development of a therapeutic agent without side effects for various diseases caused by activation of STAT3.
    Type: Grant
    Filed: June 22, 2020
    Date of Patent: November 30, 2021
    Assignee: ROPHTBIO, INC.
    Inventors: SungHo Hahm, JinTae Hong
  • Patent number: 11104732
    Abstract: The present disclosure relates to a modified cell comprising a polynucleotide encoding a secretable scFv binding SIGLEC-15 and/or encoding a dominant negative form of CD44. In embodiments, the modified cell further comprises an antigen-binding molecule, which for example, is a CAR comprising an antigen-binding domain, a transmembrane domain, and an intracellular signaling domain.
    Type: Grant
    Filed: April 23, 2020
    Date of Patent: August 31, 2021
    Inventors: Zhiyuan Cao, Chengfei Pu, Lei Xiao
  • Patent number: 11084854
    Abstract: A protease-resistant neurotrophic peptide is provided. A pharmaceutical composition including the protease-resistant neurotrophic peptide in a pharmaceutically acceptable carrier, in combination with optional adjuvants, stabilizers and/or preservatives, is also provided.
    Type: Grant
    Filed: August 12, 2020
    Date of Patent: August 10, 2021
    Inventors: Luigi Manni, Marzia Soligo
  • Patent number: 11033619
    Abstract: The invention provides a system that comprises pharmaceutical agents for use in immunotherapy for reducing the side-effects of an antigen-recognizing receptor against antigen-expressing non-target cells in an individual. The system includes an antigen-recognizing receptor that specifically recognizes an antigen on target cells and at least on one hematopoietic cell type in the individual. The antigen-recognizing receptor is exemplified by chimeric antigen receptors (CAR) be expressed on the surface of an immune effector cells. The system also includes hematopoietic cells resistant to recognition of the same antigen by the antigen-recognizing receptor.
    Type: Grant
    Filed: June 11, 2018
    Date of Patent: June 15, 2021
    Assignee: MILTENYI BIOTEC B.V. & CO. KG
    Inventors: Michael Lutteropp, Anne Richter, Andrew Kaiser, Mario Assenmacher, Stefan Miltenyi
  • Patent number: 11021540
    Abstract: Antibodies and antigen binding fragments thereof are provided that immunospecifically bind to PD-1, preferably human or mouse PD-1, and induce or promote an immune response that activates immune cell proliferation or activity. Contrary to the existing paradigm that PD-1 exclusively promotes a suppressive immune response, the disclosed antibodies and antigen binding fragments thereof, immunospecifically bind to PD-1 and cause an activating signal to be delivered to the immune cell that activates the immune cell rather than suppressing the immune cell. In one embodiment, the disclosed antibodies and antigen binding fragments thereof specifically bind to PD-1 expressed on immune cells. The binding of the disclosed antibodies and antigen binding fragments thereof to PD-1 on immune cells causes an activating signal to be transmitted into the immune cell, for example a signal that enhances or promotes cytokine production and/or activation of immune cell proliferation.
    Type: Grant
    Filed: September 7, 2018
    Date of Patent: June 1, 2021
    Inventors: Samir Khleif, Mikayel Mkrtichyan